Deep data driven and built for better biologics decisions

Proteo Quant was created to solve a recurring challenge in biologics development:

critical molecular liabilities often remain hidden until late-stage development.

Our model combines quantitative biology, kinetic analytics, and biologics developability science to support stronger candidate decisions earlier.Advancing Drug Discovery and Development Through Data, Biology, and Technology

Driven To Reduce Risks in Discovery Through Clinical Development With Deep Data-Based Protein Science, Affinity Kinetics & AI-Powered Insights

Proteo Quant provides quantitative intelligence for biologics discovery

Proteo Quant platform enables biotech and pharma teams to generate high-resolution analytical and kinetic insight for biologic candidates, thus reducing risk early on in smarter selection, stronger developability, and faster progression.

We specialize in biologics characterization, kinetic intelligence, and decision-support analytics for therapeutic proteins.

We are a science‑led organization dedicated to enabling breakthrough therapies and life‑science products by improving biologics decision-making through high-resolution analytical insight. Our multidisciplinary teams work across biology, chemistry, AI, and clinical research to deliver reliable, compliant, and scalable solutions for global drug discovery and development.

Who We Are

Our Approach

We are a next‑generation life‑sciences research and development company delivering integrated discovery, translational, and clinical solutions across biologics, vaccines, diagnostics, and advanced therapeutics. By combining deep protein science and drug development expertise with AI‑driven analytics and advanced computational platforms, we bring acceleration to innovation from concept to clinic and beyond.

Our Mission

At Proteo Quant, we blend protein science, affinity kinetics expertise with AI and machine learning to fast-track biologics and diagnostics from discovery to approved drugs and therapeutics.